Nevro Announces Full Exercise and Closing of Underwriters' Option to Purchase Additional Shares
MENLO PARK, Calif., June 23, 2015 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today announced the full exercise and closing of the option to purchase 705,882 additional shares of its common stock by the underwriters of its previously announced public offering at a public offering price of $51.00 per share, before underwriting discounts and commissions.
Including the full exercise of the underwriters' option to purchase additional shares, Nevro issued a total of 2,470,587 shares and the selling stockholders in the offering sold 2,941,175 shares, resulting in gross proceeds of approximately $126 million to Nevro and approximately $150 million to the selling stockholders, in each case, before underwriting discounts and commissions and expenses payable by Nevro.
J.P. Morgan and Morgan Stanley acted as joint book-running managers for the offering. Leerink Partners and JMP Securities acted as co-managers.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on June 2, 2015. The offering of these securities were made only by means of a prospectus, copies of which may be obtained from J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by telephone at (866) 803-9204, or from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, or by telephone at (866) 718-1649.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Nevro
Headquartered in Menlo Park, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The Senza system is the only SCS system that delivers Nevro's proprietary HF10 therapy. Senza, HF10, Nevro and the Nevro logo are trademarks of Nevro.
Investor Relations Contact:
Westwicke Partners
Lynn Pieper
(415) 202-5678
[email protected]
SOURCE Nevro Corp.
Share this article